Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ZYNE
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Zynerba Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 70.12M
- Ent value
- 45.61M
- Price/Sales
- -
- Price/Book
- 2.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.92%
- 1 year return
- 85.77%
- 3 year return
- -28.85%
- 5 year return
- -29.28%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
ZYNE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 2.42 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 53.94M |
| EPS (TTM) | -0.74 |
| FCF per share (TTM) | -0.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -38.79M |
| Net income (TTM) | -37.01M |
| EPS (TTM) | -0.74 |
| EPS (1y forward) | -0.57 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 35.97M |
| Net receivables | 1.31M |
| Total current assets | 39.29M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 394.90K |
| Total assets | 40.48M |
| Accounts payable | 2.48M |
| Short/Current long term debt | 217.88K |
| Total current liabilities | 11.46M |
| Total liabilities | 11.46M |
| Shareholder's equity | 29.02M |
| Net tangible assets | 29.02M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -31.64M |
| Capital expenditures (TTM) | 200.45K |
| Free cash flow (TTM) | -31.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -127.53% |
| Return on Assets | -91.43% |
| Return on Invested Capital | -126.58% |
| Cash Return on Invested Capital | -108.91% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ZYNE | S&P500 | |
| Current price drop from All-time high | -96.44% | -8.66% |
| Highest price drop | -99.18% | -56.47% |
| Date of highest drop | 19 May 2023 | 9 Mar 2009 |
| Avg drop from high | -79.84% | -10.99% |
| Avg time to new high | 515 days | 12 days |
| Max time to new high | 2055 days | 1805 days |
COMPANY DETAILS
Marketcap
70.12M
Marketcap category
Small-cap
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. As of October 10, 2023, Zynerba Pharmaceuticals, Inc. operates as a subsidiary of Harmony Biosciences Holdings, Inc.
Employees
25
Website
Investor relations
-
SEC filings
CEO
Armando Anido
Country
USA
City
Devon
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner